

VULVOVAGINAL CANDIDIASIS: A REAL-WORLD EVIDENCE STUDY OF THE PERCEIVED BENEFITS OF CANESTEN®

L. Zhang, R. De Salvo, A. Ehret, K. Young and S. Trapp



Objectives

Real-world evidence study, aimed to provide **consumer important information on the benefits of Canesten** (clotrimazole/fluconazole-based product) in the treatment of vulvovaginal candidiasis (VVC). The focus of the outcome is:

- > **Symptom Improvement and Relief.**
- > **Speed of Onset.**
- > **Quality of Life (QoL).**
- > **Product Attributes and Satisfaction.**

Study design

Retrospective observational study.


Web based interviews.

Population

Women who have used a Canesten product for **VVC within last 6 months.**

N=475. (UK=262 and Canada=213).

Age group



Results

45% Experienced **both internal and external symptoms.**



Discussion

- Canesten products not only **alleviate symptoms** effectively but also **enhance QoL.**
- Canesten products provide **rapid onset of relief**, particularly with topical treatments.
- Women experiencing both internal and external symptoms reported Canesten **combi pack (vaginal & external products)** to provide **faster relief of symptoms** than single product treatments.

Conclusion

The real-world evidence supports **Canesten's effectiveness** in providing **rapid relief from VVC symptoms**, significantly **improving QoL** and achieving **high consumer satisfaction**. Despite the study's limitations, we consider our findings to be robust and to add supplementary value to the information obtained from randomized trials of VVC therapies. These insights are crucial for guiding consumer choices regarding treatment options.